The Brazilian National Agency for Health Supervision (Anvisa) is discussing the possibility of issuing an emergency vaccination permit against COVID-19 using drugs that have not been registered in the country. This is reported by the newspaper O Globo with reference to sources close to the negotiations.
In particular, according to the newspaper, the department is considering the possibility of vaccinating certain groups of the population under controlled conditions until the end of ongoing clinical trials of drugs. As specified, Anvisa in this case is looking for ways to ensure the safety of vaccines until the manufacturers register them.
Anvisa has now authorized four coronavirus vaccines for clinical trials in the country. These were the medicines of Chinese company Sinovac Biotech, British-Swedish AstraZeneca, American Pfizer, and Janssen-Cilag. In addition, Brazil participates in the development of vaccines against coronavirus through the international mechanism Covax Facility. To date, the South American Ministry of Health has entered into agreements to purchase and produce 300 million doses of coronavirus vaccine.